Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations Meeting Abstract
| Authors: | Weberpals, J.; Oza, A.; Lorusso, D.; Scambia, G.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Clamp, A. R.; Leary, A.; Holloway, R. W.; Amendo Gancedo, M.; Fong, P. C.; Goh, J. C.; O'Malley, D. M.; Armstrong, D. K.; Banerjee, S.; García-Donas, J.; Swisher, E. M.; Cameron, T.; Maloney, L.; Goble, S.; Coleman, R. L.; Ledermann, J. A. |
| Abstract Title: | Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations |
| Meeting Title: | 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society (IGCS) |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 30 |
| Issue: | Supp. 3 |
| Meeting Dates: | 2020 Sep 10-13 |
| Meeting Location: | Virtual Conference |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2020-11-01 |
| Start Page: | A2 |
| End Page: | A3 |
| Language: | English |
| ACCESSION: | WOS:000616549600004 |
| DOI: | 10.1136/ijgc-2020-IGCS.3 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3; Plenary I IGCS20_1268 -- Source: Wos |
